第一型糖尿病 - VERTEX VX-880 臨床公布 1/2 期正向

2023.10.03 公布

VERTEX: VX-880 (摘要)

VX-880 (T1D)療法皆是使用幹細胞衍生並且完全分化的胰島細胞

• 恢復胰島 B 細胞功能，恢復患者調節血糖能力

• 靜脈注射

• All patients treated with VX-880 in Parts A and B have follow-up data beyond Day 90 and have demonstrated islet cell engraftment and glucose-responsive insulin production -

• All patients showed improvement across all measures of glucose control, including decreases in HbA1c, increases in blood glucose time-in-range, and reduction or elimination of insulin use -

• The two patients with at least 1 year of follow-up met the criteria for the primary endpoint of elimination of severe hypoglycemic events (SHEs) and HbA1c <7.0% -

• VX-880 was generally well tolerated(6 名受試者並未發生不良重度事件)

• Part C concurrent dosing well underway -

• 參考

  • Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting